Clinical trials, management software maker Bio-Optronics draws $30M investment
Summary
Bio-Optronics — a producer of software and services focused on clinical research, automated scheduling, and patient safety — has announced $30 million in funding from growth equity firm Mainsail Partners. The new funding will be used to accelerate product development, improve customer service capacities, and boost sales and marketing efforts, according to the company. “We did not need to raise capital to continue our growth, but rather chose to partner with Mainsail in order to invest more heavily in our products and in our customers’ success. The company’s Momentum platform targets physician and medical staff scheduling, and includes a mobile app that allows practitioners to more conveniently view their shifts. “The company’s Clinical Conductor product should benefit from the continued growth in the number and complexity of clinical trials, and the Momentum scheduling product should continue to grow rapidly as healthcare organizations stop building medical staff schedules manually and instead use software to help automate the process.” Bio-Optronics also announced that Anderson, Taylor McKinley, operating partner at Mainsail, and David Farsai, VP at Mainsail, will be joining the company’s board of directors.
Classifications
AskAI Classifications
LabelsLinked Companies
